Dysadherin expression in prostatic adenocarcinoma and its relationship with E-cadherin and β-catenin.
[BACKGROUND] We analyzed immunoexpression of Dysadherin, E-cadherin and ß-catenin proteins in prostate.
- p-value p < 0.001
- p-value P = 0.017
APA
Limani R, Kondirolli L, et al. (2025). Dysadherin expression in prostatic adenocarcinoma and its relationship with E-cadherin and β-catenin.. Future science OA, 11(1), 2494972. https://doi.org/10.1080/20565623.2025.2494972
MLA
Limani R, et al.. "Dysadherin expression in prostatic adenocarcinoma and its relationship with E-cadherin and β-catenin.." Future science OA, vol. 11, no. 1, 2025, pp. 2494972.
PMID
40292544
Abstract
[BACKGROUND] We analyzed immunoexpression of Dysadherin, E-cadherin and ß-catenin proteins in prostate.
[METHODS] 53 radical prostatectomy specimens were included. Dysadherin, E-cadherin and ß-catenin were evaluated in prostatic adenocarcinoma and in adjacent non-tumorous tissue, and correlated with clinicomorphological features in prostatic adenocarcinoma.
[RESULTS] We report cytoplasmic/membraneous and nuclear staining for Dysadherin in prostatic tissue. Cytoplasmic/membraneous expression was stronger in prostatic adenocarcinoma when compared to adjacent non-tumorous prostatic tissue (p < 0.001).
[UNLABELLED] Dysadherin positively correlated with T status (rho = 0.326, P = 0.017) and Grade Group (rho = 0.278, P = 0.044). We report no correlation with recurrence, surgical margins status, sPSA and N status. E-cadherin was negatively correlated with recurrence (rho = -0.297, P = 0.031), T status (rho = -0.430, P = 0.001), Grade Group (rho = -0.558, P < 0.001) and positive surgical margins (rho = -0.404, P = 0.003). ß-catenin negatively correlated with Grade Group (rho = -0.557, P < 0,001). No correlation was observed between Dysadherin and E-cadherin and Dysadherin and ß-catenin expression.
[CONCLUSION] Our results suggest a potential role for Dysadherin in tumor progression. No significant correlation between Dysadherin and E-cadherin or ß-catenin indicates potential independence of Dysadherin in its regulatory role in prostatic adenocarcinoma.
[METHODS] 53 radical prostatectomy specimens were included. Dysadherin, E-cadherin and ß-catenin were evaluated in prostatic adenocarcinoma and in adjacent non-tumorous tissue, and correlated with clinicomorphological features in prostatic adenocarcinoma.
[RESULTS] We report cytoplasmic/membraneous and nuclear staining for Dysadherin in prostatic tissue. Cytoplasmic/membraneous expression was stronger in prostatic adenocarcinoma when compared to adjacent non-tumorous prostatic tissue (p < 0.001).
[UNLABELLED] Dysadherin positively correlated with T status (rho = 0.326, P = 0.017) and Grade Group (rho = 0.278, P = 0.044). We report no correlation with recurrence, surgical margins status, sPSA and N status. E-cadherin was negatively correlated with recurrence (rho = -0.297, P = 0.031), T status (rho = -0.430, P = 0.001), Grade Group (rho = -0.558, P < 0.001) and positive surgical margins (rho = -0.404, P = 0.003). ß-catenin negatively correlated with Grade Group (rho = -0.557, P < 0,001). No correlation was observed between Dysadherin and E-cadherin and Dysadherin and ß-catenin expression.
[CONCLUSION] Our results suggest a potential role for Dysadherin in tumor progression. No significant correlation between Dysadherin and E-cadherin or ß-catenin indicates potential independence of Dysadherin in its regulatory role in prostatic adenocarcinoma.